Molecular characterization of Quebec Cohort of Primary Breast Cancer FFPE Tissues on the Human Cancer Panel

Analysis of 97 formalin-fixed, paraffin-embedded (FFPE) primary breast tumors using Illumina DASL microarray technology on a Custom Breast Cancer Panel and the Illumina Human Cancer Panel. Molecular markers between the pathology defined subtypes of breast cancer were assessed to hypothesize potential therapeutic targets specific to the subtypes Molecular Characterization of 97 primary breast tumor formalin-fixed, paraffin-embedded (FFPE) specimens including 24 triple negative (TN: ER-, PR-, HER2-), 9 HER2-positive (HER2+: ER-, PR-, HER2+), and 64 hormone receptor-positive (HR+: ER+ and/or PR+). 91 of the 97 specimens were characterized on the Illumina Human Cancer DASL Panel and 86 of 97 specimens were characterized on a custom Breast Cancer DASL Panel, 80 of these specimens were common to both the Human Cancer DASL Panel and the custom Breast Cancer DASL Panel.

本研究采用Illumina DASL微阵列技术，分别采用定制化乳腺癌基因检测面板（Custom Breast Cancer Panel）与Illumina人类癌症基因检测面板（Illumina Human Cancer Panel），对97份福尔马林固定石蜡包埋（formalin-fixed, paraffin-embedded, FFPE）原发性乳腺肿瘤样本进行分析。研究针对病理学定义的乳腺癌亚型之间的分子标志物展开检测，旨在提出各亚型特异性潜在治疗靶点的假说。本次纳入的97份FFPE原发性乳腺肿瘤样本中，包含24份三阴性乳腺癌（triple negative, TN: ER-, PR-, HER2-）样本、9份HER2阳性乳腺癌（HER2-positive, HER2+: ER-, PR-, HER2+）样本以及64份激素受体阳性乳腺癌（hormone receptor-positive, HR+: ER+ 且/或 PR+）样本。97份样本中，91份通过Illumina人类癌症DASL检测面板完成分子表征，86份通过定制化乳腺癌DASL检测面板完成表征，其中80份样本同时在两种检测面板上完成了分子表征。